TrialAnnals of hematology2025

Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.

Ajibade Ashaye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.